TFF3 and metabolic dysfunction-associated steatotic liver disease: Recent findings indicate that in pathological conditions such as cancer, colitis, gastric ulcers, diabetes mellitus, and non-alcoholic fatty liver disease [82,83], there are notable alterations in the expression profile and biological impacts of TFF3.